Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

October 05, 2026

Performance

52-Week Range 15.7% below 52-week high

92.91

21.1452W Low 110.1752W High

1 Week 2.4% below 1-week high

80.941W Low 95.171W High

Spyre Therapeutics, Inc. - Common Stock (SYRE) traded between $21.14 and $110.17 over the past 52 weeks and last traded at $92.91, 15.7% below its 52-week high. Over the past week it ranged between $80.94 and $95.17.

Past 12 Months

+9.7%

+8.4%

-7.1%

+29.2%

+203.8%

+278.1%

1W +$8.19

1M +$7.22

3M -$7.13

6M +$21.01

YTD +$62.33

1Y +$68.34

SYRE was +278.1% over the past year, +29.2% over six months, +203.8% year to date, +9.7% in the last week.

12 Months vs Market

SYRE

+278.1%

DIA

+10.0%

SPY

+11.7%

QQQ

+13.4%

IWM

+10.7%

Over the past 12 months SYRE returned +278.1% versus DIA (Dow) +10.0%, SPY (S&P 500) +11.7%, QQQ (Nasdaq 100) +13.4% and IWM (Russell 2000) +10.7%.

Volume & Liquidity 0.52× 3-mo avg

Today 637,158 3-mo avg 1.2M

1.1M

1.5M

1.2M

1.3M

YTD

1.1M

SYRE most recently traded 637,158 shares against a 3-month average daily volume of 1.2M.

More News

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

October 05, 2026

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

September 08, 2026

Spyre Therapeutics to Participate in Upcoming September Investor Conferences

September 03, 2026

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Wednesday's pre-market session: top gainers and losers ↗

August 26, 2026

Via Chartmill

What's going on in today's after hours session ↗

August 25, 2026

Via Chartmill

August 25, 2026

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

August 10, 2026

Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know ↗

August 06, 2026

A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know ↗

August 06, 2026

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 04, 2026

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

June 15, 2026

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

June 03, 2026

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 26, 2026

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗

May 17, 2026

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗

May 17, 2026

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗

May 17, 2026

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗

May 17, 2026

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 05, 2026

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

April 16, 2026

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

April 14, 2026

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

April 13, 2026

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

These stocks are gapping in today's session ↗

April 13, 2026

Via Chartmill

April 13, 2026